恒瑞医药
(600276)
| 流通市值：3057.46亿 | | | 总市值：3181.21亿 |
| 流通股本：63.79亿 | | | 总股本：66.37亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 24,408,762,724.19 | 15,455,583,728.11 | 8,140,565,320.77 | 31,629,416,193.83 |
| 营业收入 | 24,408,762,724.19 | 15,455,583,728.11 | 8,140,565,320.77 | 31,629,416,193.83 |
| 二、营业总成本 | 17,294,495,762.71 | 11,313,140,405.95 | 5,642,928,613.81 | 23,093,097,613.72 |
| 营业成本 | 3,225,793,225.64 | 2,113,343,029.35 | 1,090,949,138.37 | 4,362,655,815.43 |
| 税金及附加 | 236,328,939.06 | 140,873,446.74 | 64,500,090.4 | 263,597,302.01 |
| 销售费用 | 6,474,886,503.47 | 4,340,919,075 | 2,196,612,842.37 | 9,106,426,024.5 |
| 管理费用 | 2,050,805,977.37 | 1,257,485,048.12 | 617,633,379.37 | 2,806,207,717.65 |
| 研发费用 | 5,422,969,359.97 | 3,492,911,607.38 | 1,650,624,680.45 | 6,961,155,413.23 |
| 财务费用 | -116,288,242.8 | -32,391,800.64 | 22,608,482.85 | -406,944,659.1 |
| 其中:利息费用 | 3,999,191.25 | 2,998,900.37 | 448,282.31 | 14,349,097.41 |
| 其中:利息收入 | 1,016,587,340.01 | 701,326,009.94 | 322,964,432.69 | 785,387,184.81 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 803,619,673.46 | 843,222,978.34 | 129,058,814.18 | 173,573,838.21 |
| 加:投资收益 | -107,830,429.31 | -63,147,682.14 | -61,353,119.01 | -80,184,824.51 |
| 资产处置收益 | 98,249,658.44 | 40,624,532.98 | 6,750,758.28 | 4,053,134.77 |
| 资产减值损失(新) | -88,695,083.1 | -18,334,072.43 | -14,313,440.94 | -86,914,039.97 |
| 信用减值损失(新) | -10,717,109.12 | 1,723,511.73 | -10,080,310.35 | -23,881,677.14 |
| 其他收益 | 185,000,077.55 | 141,209,898.57 | 59,744,118.88 | 467,037,830.52 |
| 四、营业利润 | 7,993,893,749.4 | 5,087,742,489.21 | 2,607,443,528 | 8,990,002,841.99 |
| 加:营业外收入 | 13,018,017.95 | 7,971,889.6 | 3,542,278.83 | 7,115,616.84 |
| 减:营业外支出 | 278,281,822.47 | 143,296,910.97 | 54,123,751.29 | 289,492,920.65 |
| 五、利润总额 | 7,728,629,944.88 | 4,952,417,467.84 | 2,556,862,055.54 | 8,707,625,538.18 |
| 减:所得税费用 | 805,475,886.82 | 487,135,047.96 | 275,867,350.2 | 990,623,292.4 |
| 六、净利润 | 6,923,154,058.06 | 4,465,282,419.88 | 2,280,994,705.34 | 7,717,002,245.78 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 6,923,154,058.06 | 4,465,282,419.88 | 2,280,994,705.34 | 7,717,002,245.78 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 6,923,404,216.25 | 4,465,439,428.1 | 2,282,268,233.13 | 7,711,054,811.98 |
| 少数股东损益 | -250,158.19 | -157,008.22 | -1,273,527.79 | 5,947,433.8 |
| 扣除非经常损益后的净利润 | 6,243,162,302.63 | 3,729,589,028.7 | 2,172,398,804.54 | 7,413,405,567.05 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.05 | 0.68 | 0.34 | 1.19 |
| (二)稀释每股收益 | 1.05 | 0.68 | 0.34 | 1.18 |
| 八、其他综合收益 | -48,149,058.09 | -31,800,666.03 | -13,182,740.49 | 10,995,435.22 |
| 归属于母公司股东的其他综合收益 | -45,687,730.66 | -29,975,797.37 | -12,265,957.44 | 10,992,174.7 |
| 九、综合收益总额 | 6,875,004,999.97 | 4,433,481,753.85 | 2,267,811,964.85 | 7,727,997,681 |
| 归属于母公司股东的综合收益总额 | 6,877,716,485.59 | 4,435,463,630.73 | 2,270,002,275.69 | 7,722,046,986.68 |
| 归属于少数股东的综合收益总额 | -2,711,485.62 | -1,981,876.88 | -2,190,310.84 | 5,950,694.32 |
| 公告日期 | 2026-10-28 | 2026-08-20 | 2026-04-23 | 2026-03-26 |
| 审计意见(境内) | | | | 标准无保留意见 |